This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

"Only a patient can really appreciate how much ringing the bell matters. So the day he hung it up, it was the most joyous ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

BostonGene collaborates with BeiGene to advance biomarker discovery in mantle cell lymphoma: Waltham, Massachusetts Thursday, February 13, 2025, 09:00 Hrs [IST] BostonGene, a lead ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...